ORPHA:252128
Malignant peripheral nerve sheath tumor with perineurial differentiation
Also known as: Malignant perineurioma
Publications
67
46.2th percentile
Trials
0
Interventional, condition-specific
Researchers
366
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
Malignant peripheral nerve sheath tumor with perineurial differentiation is a rare soft tissue sarcoma composed predominantly of spindle-shaped neoplastic cells showing perineurial differentiation and displaying abundant cellular pleomorphism or anaplasia, frequent mitoses, tumor necrosis and high metastatic potential. It often presents as a soft, painless, solid mass in subcutaneous tissues of the trunk or limbs, but tumors have also been described in the facial area, mediastinum, retroperitoneum, pancreas, paravertebral column and the pelvic soft tissues. Frequent local recurrence and distant metastatic spread has been reported.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016751
- UMLS:C1266188
- NCIT:C66845
Additional Mondo synonyms (5)
malignant peripheral nerve sheath tumor with perineurial differentiation · malignant peripheral nerve sheath tumour with perineurial differentiation · perineurial malignant peripheral nerve sheath tumor · perineurial malignant peripheral nerve sheath tumour · perineurioma, malignant
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
67 matched papers (34 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
67
67 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
67 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
34 in the last 10 years · high confidence · 46.2th percentile (publications denominator)
Phrase hits: 67 · MeSH hits: 0
Who's working on it?
366
Distinct author names in 67 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Scheithauer BW3 papers · 2012
Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA. scheithauer.bernd@mayo.edu
Papers in Europe PMC - 02Bauchet F2 papers · 2020
Neuro-Oncology Group of Languedoc Roussillon, Institut du Cancer de Montpellier, Montpellier, France.
Papers in Europe PMC - 03Bauchet L2 papers · 2020
Department of Neurosurgery, Gui de Chauliac Hospital, University Hospital Center (CHU) Montpellier, Montpellier University Medical Center, Montpellier, France.
Papers in Europe PMC - 04Bessaoud F2 papers · 2020
Tumor Registry of the Hérault, Institut du Cancer de Montpellier, Montpellier, France.
Papers in Europe PMC - 05Darlix A2 papers · 2020
Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.
Papers in Europe PMC - 06Figarella-Branger D2 papers · 2020
Aix-Marseille University, National Center for Scientific Research, Institute of Neuro-Physiopathology, Marseille, France.
Papers in Europe PMC - 07Hirose T2 papers · 2014
First Department of Pathology, University of Tokushima School of Medicine, Japan.
Papers in Europe PMC - 08Mathieu-Daudé H2 papers · 2020
Neuro-Oncology Group of Languedoc Roussillon, Institut du Cancer de Montpellier, Montpellier, France.
Papers in Europe PMC - 09Michal M2 papers · 2005Papers in Europe PMC
- 10Rigau V2 papers · 2020
Department of Pathology, Centre Hospitalier Universitaire, Hôpital Gui de Chauliac, Montpellier cedex, France. v-rigau@chu-montpellier.fr
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Malignant peripheral nerve sheath tumor with perineurial differentiation" OR "Malignant perineurioma" OR "malignant peripheral nerve sheath tumour with perineurial differentiation" OR "perineurial malignant peripheral nerve sheath tumor" OR "perineurial malignant peripheral nerve sheath tumour" OR "perineurioma, malignant"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Malignant peripheral nerve sheath tumor with perineurial differentiation" OR "Malignant perineurioma" OR "malignant peripheral nerve sheath tumour with perineurial differentiation" OR "perineurial malignant peripheral nerve sheath tumor" OR "perineurial malignant peripheral nerve sheath tumour" OR "perineurioma, malignant"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T10:59:35.657Z